HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Federal Agencies Shut Down Church Group's Sales Of Bleach Mixture Promoted As COVID-19 Cure

Executive Summary

The combination of Genesis II Church's rejection of FDA's warning, the potential for serious adverse events linked to its chlorine dioxide formulation and its claims the product treats COVID-19 led FDA to seek an injunction to stop sales of the product a week after it warned the group.

You may also be interested in...



US COVID-19 Fraud: Tincture, Sanitizer Warnings, Criminal Contempt Charges And Civil Settlement

FDA’s latest COVID-19 warnings note fewer violative claims than identified in previous warnings to consumer health firms. One had a single noncompliant claim on its website, while another’s violations included identifying potential symptoms of COVID-19. Four men associated with a Florida church face counts of conspiracy to defraud the US and of contempt of court stemming from COVID-1 claims for a bleach solution.

Commissioner Expects Pandemic Response To Continue Steering US FDA Decisions, Priorities

FDA faces unprecedented challenges responding to pandemic, needing to balance urgency, speed, safety and transparency against a fast-moving background. Hahn, who spoke at a recent medical device industry conference and will testify at a congressional hearing on 23 June, says he has focused on making decisions supported by data and science, and updating those decisions as more information became available.

Next Call Could Be Regulators After hGH Direct Seller Ignores Industry Self-Regulation Process

Direct seller New U Life may face regulatory scrutiny after two BBB National Programs, Inc. industry self-regulation programs reported it failed to stop using bogus health claims, including treating COVID-19.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel